loader
Please Wait
Applying Filters...

Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about AM000363, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    AM000363

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    PharmaCompass

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    2D Structure
    Also known as: 97048-13-0, 146479-72-3, 1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide, Fertinex; fertinorm; metrodin; orgafol; urofollitrophin, 26995-91-5, Schembl19712185
    Molecular Formula
    C42H65N11O12S2
    Molecular Weight
    980.2  g/mol
    InChI Key
    ZDRRIRUAESZNIH-UHFFFAOYSA-N
    A protein extract of human menopausal urine in which LUTEINIZING HORMONE has been partially or completely removed. Urofollitropin represents FOLLICLE STIMULATING HORMONE from the urine.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
    2.1.2 InChI
    InChI=1S/C42H65N11O12S2/c1-6-21(4)33-40(63)52-34(22(5)54)41(64)49-28(16-31(44)56)37(60)50-29(19-67-66-18-25(43)35(58)47-27(38(61)51-33)15-23-9-11-24(55)12-10-23)42(65)53-13-7-8-30(53)39(62)48-26(14-20(2)3)36(59)46-17-32(45)57/h9-12,20-22,25-30,33-34,54-55H,6-8,13-19,43H2,1-5H3,(H2,44,56)(H2,45,57)(H,46,59)(H,47,58)(H,48,62)(H,49,64)(H,50,60)(H,51,61)(H,52,63)
    2.1.3 InChI Key
    ZDRRIRUAESZNIH-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. Bravelle

    2. Fertinex

    3. Follicle Stimulating Hormone, Human Urine

    4. Follicle-stimulating Hormone, Human Urine

    5. Follitrin

    6. High Purity, Metrodin

    7. Human Fsh, Urinary

    8. Metrodin

    9. Metrodin High Purity

    10. Metrodin Hp

    11. Neo Fertinorm

    12. Urinary Human Fsh

    2.2.2 Depositor-Supplied Synonyms

    1. 97048-13-0

    2. 146479-72-3

    3. 1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide

    4. Fertinex; Fertinorm; Metrodin; Orgafol; Urofollitrophin

    5. 26995-91-5

    6. Schembl19712185

    7. Dtxsid10869286

    8. Q4006490

    9. 1-{19-amino-7-(2-amino-2-oxoethyl)-13-(butan-2-yl)-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl}prolylleucylglycinamide

    2.3 Create Date
    2005-08-08
    3 Chemical and Physical Properties
    Molecular Weight 980.2 g/mol
    Molecular Formula C42H65N11O12S2
    XLogP3-1.5
    Hydrogen Bond Donor Count12
    Hydrogen Bond Acceptor Count15
    Rotatable Bond Count15
    Exact Mass979.42555890 g/mol
    Monoisotopic Mass979.42555890 g/mol
    Topological Polar Surface Area427 Ų
    Heavy Atom Count67
    Formal Charge0
    Complexity1790
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count10
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    For treatment of female infertility

    FDA Label

    Treatment of hypogonadotrophic hypogonadism, Treatment of female infertility

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Used for the treatment of female infertility, urofollitropin or follicle stimulating hormone (FSH) stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH, the active component of urofollitropin is the primary hormone responsible for follicular recruitment and development.

    5.2 ATC Code

    G - Genito urinary system and sex hormones

    G03 - Sex hormones and modulators of the genital system

    G03G - Gonadotropins and other ovulation stimulants

    G03GA - Gonadotropins

    G03GA04 - Urofollitropin

    5.3 Absorption, Distribution and Excretion

    Absorption

    74%

    Route of Elimination

    Via liver and kidneys

    Volume of Distribution

    Time to peak in plasma: IM: 17 hours (single dose), 11 hours (multiple doses) SubQ: 21 hours (single dose), 10 hours (multiple doses)

    5.4 Biological Half-Life

    Circulation half life of 3-4 hours, elimination half life of 35-40 hours

    5.5 Mechanism of Action

    FSH binds to the follicle stimulating hormone receptor which is a G-coupled transmembrane receptor. Binding of the FSH to its receptor seems to induce phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signaling pathway, which is known to regulate many other metabolic and related survival/maturation functions in cells.

    Post Enquiry
    POST ENQUIRY